Results 101 to 110 of about 5,464 (192)

PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Vitae, 2009
Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant
Iván F. PALOMO G, Constanza I. TORRES U., Rodrigo E. MOORE-Carrasco., Marcelo A. ALARCÓN L., Patricio J. MARAGAÑO L.   +4 more
doaj  

Cost Effectiveness of Abciximab During Routine Medical Practice

Objective: To estimate the cost per ischaemic event (death, nonfatal myocardial infarction, subsequent revascularisation procedure) avoided at 6 months in high risk patients undergoing coronary revascularisation treated with abciximab during routine ...
C. Daniel Mullins, Shelby Ogilvie Reed, Laurence S. Magder   +2 more
core  

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel

, 2008
Das 30-Tage-Ergebnis der ISAR-REACT-Studie erbrachte keinen klinischen Vorteil durch Abciximab bei Patienten mit perkutaner Koronarimplantation und einer Gabe von 600mg Clopidogrel mindestens zwei Stunden vor dem Eingriff.
Drescher, Andrea
core  

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction [PDF]

, 2014
J. P. Howard, C. Knight, Weerackody, R, Howard, JP, Antoniou, S, A. Mathur, Wragg, A, P. Wright, Knight, C, Rathod, K, R. Weerackody, S. Gallagher, S. Antoniou, K. Rathod, Jones, DA, D. A. Jones, A. Wragg, Gallagher, S, Wright, P, Mathur, A   +19 more
core   +1 more source

Los inhibidores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos.

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2012
Los inhibidores de los receptores IIb/IIIa, un nuevo grupo de antiagregantes plaquetarios, son potentes bloqueadores del receptor que media la agregación plaquetaria y de ese modo bloquean la vía final común de la formación del trombo plaquetario.
Fidel Manuel Cáceres Lóriga, Horacio Pérez López   +1 more
doaj  

Revisiting Antiplatelet Therapy in Acute Carotid Tandem Lesions. [PDF]

J Clin Med
Zupan M, Straus L, Kermer P, Papanagiotou P, Frol S.   +4 more
europepmc   +1 more source

Response to letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". [PDF]

Cardiol J
Altınkaya O, Aydemir S, Özkoç M.
europepmc   +1 more source

Angiographics evalutation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI

, 2005
Background: Recent data suggest that the intracoronary (i.c.) administration of a systemic bolus dose of abciximab during PCI may increase the efficacy of this antiplatelet drug. However, the effect of i.c.
Trani, Carlo, Crea, Filippo, Burzotta, Francesco, Biondi Zoccai, Giuseppe, Mongiardo, Rocco, Rebuzzi, Antonio Giuseppe, Niccoli, Giampaolo, Romagnoli, Enrico, Mazzari, Mario Attilio, De Vita, Maria   +9 more
core  

A Paradoxical Role of ADAMTS13: Enhancing Collagen-Induced Platelet Aggregation and Activation via AKT Phosphorylation. [PDF]

Thromb Haemost
Dong H, Mao Y, Zheng XL.
europepmc   +1 more source

Response to the response to the letter: "The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing PCI and receiving abciximab". [PDF]

Cardiol J
Umińska JM.
europepmc   +1 more source